<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pharmacotherapy for social anxiety disorder in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pharmacotherapy for social anxiety disorder in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pharmacotherapy for social anxiety disorder in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Murray B Stein, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter P Roy-Byrne, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Friedman, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 06, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H13589961"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Social anxiety disorder (SAD), also known as social phobia, is a condition marked by extreme fear of situations that involve possible scrutiny by others. The individual is concerned that embarrassment or humiliation will result, and so they avoid such situations or endures them with intense anxiety.</p><p>SAD is a prevalent condition, estimated to affect between 4 and 10 percent of the adult United States population over a 12-month period. SAD typically begins in childhood or adolescence and, untreated, can be associated with the subsequent development of major depression, substance use disorder, and other mental health problems. The disorder can be associated with extensive functional impairment and reduced quality of life [<a href="#rid1">1</a>].</p><p>This topic addresses the pharmacologic treatment of SAD. Discussed separately are epidemiology, pathogenesis, clinical manifestations, and diagnosis of SAD; psychotherapy for SAD; and fears and specific phobias in children. (See  <a class="medical medical_review" href="/d/html/15537.html" rel="external">"Social anxiety disorder in adults: Epidemiology, clinical features, assessment, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/14635.html" rel="external">"Social anxiety disorder in adults: Psychotherapy"</a> and  <a class="medical medical_review" href="/d/html/1226.html" rel="external">"Overview of fears and phobias in children and adolescents"</a>.)</p><p class="headingAnchor" id="H4191388684"><span class="h1">APPROACH TO TREATMENT</span><span class="headingEndMark"> — </span>Our approach to selecting among treatments for social anxiety disorder, including the use of pharmacotherapy and psychotherapy, is discussed separately. (See  <a class="medical medical_review" href="/d/html/108042.html" rel="external">"Social anxiety disorder in adults: Treatment overview"</a>.)</p><p class="headingAnchor" id="H999627688"><span class="h1">TYPES OF SOCIAL ANXIETY DISORDER</span><span class="headingEndMark"> — </span>In the transition from the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) to DSM-5, the subtypes of generalized and nongeneralized social anxiety disorder (SAD) were replaced by SAD and SAD, performance only, respectively [<a href="#rid2">2</a>]. The guidance that follows applies to SAD. Pharmacotherapy for performance-only SAD is discussed separately, later in the topic. (See <a class="local">'Social anxiety disorder, performance only'</a> below.)</p><p class="headingAnchor" id="H13589968"><span class="h1">MONOTHERAPY</span><span class="headingEndMark"> — </span>Several classes of drugs are used to treat social anxiety disorder (SAD), including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), and benzodiazepines. Pharmacologic treatment is quite different for the performance-only version of SAD compared with the general form of SAD (known prior to DSM-5 as nongeneralized and generalized SAD).</p><p>Whenever pharmacotherapy is prescribed for SAD, it is good clinical practice to recommend to the patient that they enter previously feared social situations to “test out” the effects of the medication and to learn that these situations are safe and can be tolerated. Although there are no research data to support this claim, there is some reason to believe that those patients who do the most “practicing” and “expanding of their social horizons” while on medication are the ones who have the best longer-term outcomes.</p><p class="headingAnchor" id="H13589982"><span class="h2">Selective serotonin reuptake inhibitors</span><span class="headingEndMark"> — </span>A meta-analysis of seven trials that compared SSRIs with placebo in a total of 896 patients with SAD found that SSRIs resulted in greater symptom reduction compared with placebo and had a moderate effect size [<a href="#rid3">3</a>]. SSRIs are the best studied and the most commonly prescribed of the medication treatments for SAD [<a href="#rid4">4</a>]. The SSRI <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a> was the first medication to receive approval from the Food and Drug Administration (FDA) in the United States for SAD [<a href="#rid5">5</a>].</p><p>As an example, a clinical trial randomly assigned 183 patients with SAD to receive <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a> (20 to 50 mg) or placebo for 11 weeks. Patients receiving paroxetine were more likely to be “much improved” or “very much improved” at the end of treatment with paroxetine compared with patients on placebo (55 versus 24 percent). The mean score on the Liebowitz Social Anxiety Scale was reduced in the paroxetine group compared with the placebo group (39 versus 17 percent).</p><p>The clinical effects of SSRI treatment for SAD typically require four to six weeks to have a significant impact; maximal benefit can require as long as 16 weeks [<a href="#rid6">6</a>]. Patients should be encouraged to “try out” the medication by engaging in social situations that typically result in anxiety and to report back about their response. One of the first indications of response is the patient’s report of feeling less “self-conscious” in typical social situations. Higher doses of SSRIs typically result in better outcomes, so the dose is usually pushed to the maximum tolerated by the individual (unless an excellent response is attained at a lower dose, at which point the dose would be held there to ascertain stability of the response).</p><p>Although some SSRIs have been more extensively studied than others in the treatment of SAD, there is no evidence of superiority of one SSRI over another. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">Paroxetine</a> can be started at 10 mg/day taken orally and increased to a therapeutic dose of 20 mg/day after a few days. If the patient does not respond after a six-week trial, the dose can be increased in 10 mg increments every few weeks to a maximum of 60 mg/day.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">Sertraline</a> can be started at 50 mg/day taken orally and, if the patients does not respond after six weeks, can be increased in 50 mg increments every few weeks to a maximum of 250 mg/day.</p><p></p><p>Common side effects of SSRIs include restlessness, agitation, headache, diarrhea, nausea and insomnia. SSRIs also cause sexual dysfunction in as many as 50 percent of patients. (See  <a class="medical medical_review" href="/d/html/14675.html" rel="external">"Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects"</a> and  <a class="medical medical_review" href="/d/html/1706.html" rel="external">"Sexual dysfunction caused by selective serotonin reuptake inhibitors (SSRIs): Management"</a>.)</p><p>Many of the side effects can be reduced or avoided by starting the medication at lower doses and increasing it gradually. See table for standard and lower initial doses as well as the range of therapeutic doses for SSRIs  (<a class="graphic graphic_table graphicRef81315" href="/d/graphic/81315.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H13589989"><span class="h2">Serotonin-norepinephrine reuptake inhibitors</span><span class="headingEndMark"> — </span>Although less well studied than the SSRIs, the SNRI <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a> extended release appears to be equally effective for SAD on the basis of a comparable effect size compared with various SSRIs in meta-analysis [<a href="#rid7">7-10</a>].</p><p>As an example, a clinical trial randomly assigned 440 patients with SAD to treatment with <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a> (75 to 225 mg daily extended release), <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a> (20 to 50 mg daily), or placebo [<a href="#rid8">8</a>]. After 12 weeks, response rates were similar in the venlafaxine and paroxetine groups, both of which were superior to placebo (59 and 63 versus 36 percent response, respectively). Medication discontinuation rates were similar with venlafaxine and paroxetine, but adverse events leading to a reduction in dosage were more common with venlafaxine (16 versus 8 percent).</p><p><a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">Venlafaxine</a> can be started at 37.5 mg/day taken orally and increased to a dose within the therapeutic range, between 75 and 225 mg/day  (<a class="graphic graphic_table graphicRef81315" href="/d/graphic/81315.html" rel="external">table 1</a>). SSRI recommendations regarding gradual titration, trial duration, and dose increases apply to SNRIs as well.</p><p>The most common side effects of <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a> are nausea, dizziness, insomnia, sedation, and constipation. Venlafaxine may cause elevations in blood pressure. Though usually small, the increases can be significant in some patients. The medication should be avoided in patients with hypertension, and blood pressure should be monitored during use. (See  <a class="medical medical_review" href="/d/html/1713.html" rel="external">"Serotonin-norepinephrine reuptake inhibitors: Pharmacology, administration, and side effects"</a>.)</p><p>There are no published data from controlled trials on the use of another marketed SNRI, <a class="drug drug_general" data-topicid="8484" href="/d/drug information/8484.html" rel="external">duloxetine</a>, in the treatment of SAD.</p><p class="headingAnchor" id="H13589996"><span class="h2">Monoamine oxidase inhibitors</span><span class="headingEndMark"> — </span>The MAOIs have the longest track record of use for SAD, having been essentially the only pharmacotherapy available (though never FDA approved) for SAD prior to the advent of the SSRIs. However, side effects and dietary restrictions limit their use. MAOIs are generally reserved for SAD refractory to other treatments. Some practitioners feel that MAOIs are more effective than SSRIs or SNRIs, though no comparative efficacy trials have been conducted to substantiate this belief. (See  <a class="medical medical_review" href="/d/html/1715.html" rel="external">"Monoamine oxidase inhibitors (MAOIs): Pharmacology, administration, safety, and side effects"</a>.)</p><p>Several randomized trials have found that <a class="drug drug_general" data-topicid="9762" href="/d/drug information/9762.html" rel="external">phenelzine</a> is an efficacious treatment for SAD, with approximately one-half of patients responding with a clinically significant reduction in symptoms [<a href="#rid3">3</a>]. A 2010 randomized trial that included a phenelzine arm found a response rate of 54 percent for phenelzine compared with 33 percent for placebo [<a href="#rid11">11</a>]. Phenelzine is typically started at 15 mg once or twice daily, and increased to a total dose of 60 to 90 mg/day based on response. It can take four to six weeks for a response to occur, and longer for maximal response to be attained.</p><p>MAOIs cause inhibition of the MAO enzyme. Irreversible MAOIs, such as <a class="drug drug_general" data-topicid="9762" href="/d/drug information/9762.html" rel="external">phenelzine</a>, are incompatible with certain foods and medications (eg, cheese, aged meats, alcohol, over-the-counter cold preparations). A potentially fatal hypertensive reaction can occur if users of MAOIs consume food containing tyramine; thus, use of irreversible MAOIs must be accompanied by a low tyramine diet. Their use is also contraindicated with other antidepressants, and over-the-counter or prescribed medications containing sympathomimetic stimulants or <a class="drug drug_general" data-topicid="8893" href="/d/drug information/8893.html" rel="external">dextromethorphan</a>.</p><p>Other adverse effects common at therapeutic doses include postural hypotension, insomnia, paradoxical daytime sedation, sexual dysfunction, and weight gain. In many instances, these side effects can be dose limiting.</p><p class="headingAnchor" id="H13590017"><span class="h2">Benzodiazepines</span><span class="headingEndMark"> — </span>Two, small randomized trials found the high-potency benzodiazepines, <a class="drug drug_general" data-topicid="8453" href="/d/drug information/8453.html" rel="external">alprazolam</a> [<a href="#rid12">12</a>] and <a class="drug drug_general" data-topicid="9284" href="/d/drug information/9284.html" rel="external">clonazepam</a> [<a href="#rid13">13</a>], to be efficacious as monotherapy in the reduction of SAD symptoms. Clonazepam, a longer-acting agent with a slower rate of onset, seems to be more commonly used for SAD than other benzodiazepines. Sedation, the principal dose-limiting adverse effect, can be minimized by starting with low doses and titrating upwards slowly until a satisfactory response is achieved. As either monotherapy or in augmenting a serotonin reuptake inhibitor, clonazepam can be started at 0.25 to 0.50 mg twice daily, and increased to a maximum of 2 mg twice daily.</p><p class="headingAnchor" id="H3250914566"><span class="h3">Benzodiazepines and SUD history</span><span class="headingEndMark"> — </span>Sedation and the potential for misuse and physiologic dependence limit the usefulness of these agents, which are generally avoided in patients with a history of a substance use disorder (SUD). If other agents are not effective, however, patients with history of an SUD could be judiciously prescribed a benzodiazepine, provided that the SUD was not active and the patient’s use of the medication were carefully monitored.</p><p class="headingAnchor" id="H1492676204"><span class="h2">Gabapentin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">Gabapentin</a> (an anticonvulsant) has demonstrated modest effectiveness (response rates &lt;45 percent) for SAD [<a href="#rid14">14</a>] in a randomized clinical trial. Sixty-nine patients were randomly assigned to receive double-blind treatment with either gabapentin (dosed flexibly between 900 and 3600 mg daily in three divided doses) or placebo for 14 weeks. Patients receiving gabapentin experienced reduced SAD symptoms compared with patients receiving placebo. Adverse events were consistent with the known side effect profile of gabapentin (eg, dizziness, dry mouth, somnolence).</p><p>Based upon case reports and human studies, the United States Food and Drug Administration issued a safety alert in 2019, warning that <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> may be associated with respiratory depression when administered to patients receiving central nervous system depressants or patients with underlying respiratory impairment [<a href="#rid15">15</a>]. In prescribing gabapentin to patients with these risk factors, it is prudent to start the drug at a relatively low dose (eg, 100 mg three times daily) and monitor patients for symptoms of respiratory depression (eg, unusual dizziness, dyspnea, or extreme sedation).</p><p class="headingAnchor" id="H1664583588"><span class="h2">Pregabalin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">Pregabalin</a>, a compound related to <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a>, has demonstrated modest effectiveness (response rates &lt;45 percent) for DSM-IV generalized SAD [<a href="#rid16">16</a>]. Pregabalin was approved in 2006 for the treatment of anxiety in Europe [<a href="#rid17">17,18</a>]. The medication inhibits calcium currents via high-voltage-activated channels containing the a2d-1 subunit, though the relationship of this mechanism to its efficacy for anxiety is not known. Side effects include sedation and dizziness. Tolerance, withdrawal, and dependence are possible, but pregabalin is generally better tolerated than benzodiazepines. Doses of pregabalin for SAD typically range from 150 to 600 mg per day.</p><p>The United States Food and Drug Administration issued a safety alert in 2019, warning that gabapentinoids may be associated with respiratory depression. (See <a class="local">'Gabapentin'</a> above.)</p><p class="headingAnchor" id="H4155389322"><span class="h2">Other agents</span><span class="headingEndMark"> — </span>Other medications have yielded mixed or negative results in clinical trials, or have not been sufficiently tested:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Moclobemide</strong><strong> </strong>– <a class="drug drug_general" data-topicid="10059" href="/d/drug information/10059.html" rel="external">Moclobemide</a>, a reversible MAOI selective for inhibition of MAO-A, has shown, at best, mixed results in randomized controlled trials of SAD [<a href="#rid19">19-21</a>]. Moclobemide is not marketed in the United States, but is available in many other countries. In contrast to non-reversible MAOIs (such as <a class="drug drug_general" data-topicid="9762" href="/d/drug information/9762.html" rel="external">phenelzine</a> or <a class="drug drug_general" data-topicid="10012" href="/d/drug information/10012.html" rel="external">tranylcypromine</a>), moclobemide does not require a low tyramine diet, and generally has fewer adverse effects overall.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mirtazapine</strong> – <a class="drug drug_general" data-topicid="9656" href="/d/drug information/9656.html" rel="external">Mirtazapine</a> has shown mixed results in patients with SAD. In a randomized trial of 66 women with SAD, mirtazapine (30 mg a day) was found to be efficacious for SAD compared with placebo [<a href="#rid22">22</a>]. In a more recent randomized controlled trial of 60 males and females with generalized SAD randomized to either 30 to 45 mg/day of the medication or placebo for 12 weeks, mirtazapine was no more effective than placebo (13 versus 13 percent response rate).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta-blockers </strong>–<strong> </strong>Beta-blockers are not an effective treatment for SAD [<a href="#rid23">23,24</a>], but are effective for the performance-only SAD subtype. (See <a class="local">'Social anxiety disorder, performance only'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tricyclic antidepressants (TCAs)</strong> – The TCAs have not been well studied in clinical trials of patients with SAD. A small open-label trial of <a class="drug drug_general" data-topicid="8554" href="/d/drug information/8554.html" rel="external">imipramine</a> suggested that it was not effective. It is possible that TCAs with more potent serotonergic reuptake blockade (eg, <a class="drug drug_general" data-topicid="9283" href="/d/drug information/9283.html" rel="external">clomipramine</a>) might be useful, but this is unknown.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Second-generation antipsychotics </strong>–<strong> </strong>Very small randomized controlled trials of <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> and <a class="drug drug_general" data-topicid="9570" href="/d/drug information/9570.html" rel="external">quetiapine</a> suggested that these atypical (or “second-generation”) antipsychotics might be effective for SAD [<a href="#rid25">25,26</a>]. Considerable further study is needed as well as consideration of metabolic side effects of these agents [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Buspirone</strong> – The limited available data suggest that <a class="drug drug_general" data-topicid="9172" href="/d/drug information/9172.html" rel="external">buspirone</a> is ineffective as monotherapy for SAD [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atomoxetine</strong><strong> </strong>– <a class="drug drug_general" data-topicid="8787" href="/d/drug information/8787.html" rel="external">Atomoxetine</a>, an SNRI (marketed for the treatment of attention deficit disorder/hyperactivity [ADHD]), was not shown to be effective for DSM-IV generalized SAD in a small randomized controlled trial [<a href="#rid29">29</a>]. However, there is some evidence from a trial in adults with comorbid ADHD and SAD [<a href="#rid30">30</a>] that atomoxetine may be helpful for both ADHD and SAD symptoms in patients who have both.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oxytocin</strong><strong> </strong>–<strong> </strong>Intranasal oxytocin (24 international units) versus placebo has been shown to improve some social behaviors and anxious appearance in 40 patients with SAD [<a href="#rid31">31</a>], but an effect on symptoms or overall functioning was not observed in that study [<a href="#rid31">31</a>] or in an earlier placebo-controlled trial [<a href="#rid32">32</a>].</p><p></p><p class="headingAnchor" id="H13590031"><span class="h1">AUGMENTATION</span><span class="headingEndMark"> — </span>A substantial number of patients with social anxiety disorder (SAD) respond only partially to monotherapy [<a href="#rid4">4</a>], leading to clinical trials in DSM-IV generalized SAD of medications augmenting selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) with other agents:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Buspirone</strong><strong> </strong>– A small uncontrolled trial found that 7 of 10 patients partially responsive to SSRIs appeared to benefit from augmentation with <a class="drug drug_general" data-topicid="9172" href="/d/drug information/9172.html" rel="external">buspirone</a> [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clonazepam</strong> – Randomized trials have found some evidence in support of augmentation of an SSRI with <a class="drug drug_general" data-topicid="9284" href="/d/drug information/9284.html" rel="external">clonazepam</a> [<a href="#rid34">34,35</a>]. As an example, in the larger trial, 181 patients with social anxiety disorder who had no more than a partial response to 10 weeks of <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a> were randomly assigned to 12 weeks of continuation on sertraline augmented by either clonazepam or placebo [<a href="#rid35">35</a>]. (A third arm, in which patients were switched from sertraline to <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a>, is described separately.) (See  <a class="medical medical_review" href="/d/html/108042.html" rel="external">"Social anxiety disorder in adults: Treatment overview"</a>.)</p><p></p><p class="bulletIndent1">The proportion of patients responding to treatment (defined as a Liebowitz Social Anxiety Scale [LSAS] score &lt;50) was greater in patients receiving <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a> plus <a class="drug drug_general" data-topicid="9284" href="/d/drug information/9284.html" rel="external">clonazepam</a> compared to the other two groups. Patients receiving sertraline plus clonazepam had a clinically significant decrease in LSAS severity compared to patients receiving sertraline plus placebo. A numerical advantage favoring a higher rate of remission (an LSAS score ≤30) in patients receiving sertraline plus clonazepam compared with patients continuing on sertraline plus placebo and to patients switched to <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a> (27 versus 17 and 19 percent); the results did not reach statistical significance.</p><p></p><p class="bulletIndent1">The use of benzodiazepines in patients with a history of a substance use disorder is described above. (See <a class="local">'Benzodiazepines and SUD history'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pindolol</strong> – A small randomized trial did not show a benefit of augmenting <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a> with the beta-blocker <a class="drug drug_general" data-topicid="9774" href="/d/drug information/9774.html" rel="external">pindolol</a> compared to placebo augmentation [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Monoamine oxidase inhibitors</strong> – Monoamine oxidase inhibitors should not be combined with other antidepressants due to the risk of serotonin syndrome. (See  <a class="medical medical_review" href="/d/html/301.html" rel="external">"Serotonin syndrome (serotonin toxicity)"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Ketamine</strong> – A small randomized clinical trial of a single dose of intravenous <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a> (0.5 mg/kg over 40 minutes) versus placebo in 18 adults with SAD found that patients were more likely to exhibit a treatment response (defined as &gt;35 percent reduction on the LSAS) after ketamine relative to placebo in the first two weeks following infusion (33.3 versus 0 percent) [<a href="#rid37">37</a>]. The response rate to both treatments is low. More work is needed to determine the efficacy and safety of ketamine infusions for SAD.</p><p></p><p class="headingAnchor" id="H2140761904"><span class="h1">SOCIAL ANXIETY DISORDER, PERFORMANCE ONLY</span><span class="headingEndMark"> — </span>In the transition from DSM-IV to DSM-5, the subtypes of generalized and nongeneralized social anxiety disorder (SAD) were replaced by SAD and SAD, performance only (specifier) [<a href="#rid38">38</a>].</p><p>Medication treatment is often prescribed on an "as needed" basis for performance-only SAD. We suggest benzodiazepines or beta-blockers as first-line medication treatment. Administering a test dose prior to treatment, at the same dose intended to be used prior to the performance situations(s), can be useful to assess the drug's effects.</p><p class="headingAnchor" id="H2832862984"><span class="h2">Benzodiazepines</span><span class="headingEndMark"> — </span>Benzodiazepines can also be used on an "as needed" basis to treat performance-only SAD [<a href="#rid39">39</a>]. <a class="drug drug_general" data-topicid="9284" href="/d/drug information/9284.html" rel="external">Clonazepam</a> 0.25 to 1 mg or <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">lorazepam</a> 0.5 to 2 mg can be given 30 to 60 minutes before the performance. Tolerance and physical dependence are not a concern with occasional use. But the potential for misuse, highest in persons with a history of alcohol or other substance use, should also limit their use in this context.</p><p>Sedation can be a side effect of benzodiazepines, particularly at higher doses. For this reason, the patient should be encouraged to try out the medication in advance of a potentially precipitating event to determine how well it is tolerated and to see if it is efficacious. The prescribing physician may need to fine-tune the dose for the individual. Patients may have used alcohol in the past to cope with similar situations and should be explicitly cautioned not to mix alcohol with benzodiazepines.</p><p class="headingAnchor" id="H4289994311"><span class="h2">Beta-adrenergic blockers</span><span class="headingEndMark"> — </span>There is no evidence from clinical trials on the effectiveness of beta-blockers (such as <a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">propranolol</a>) in the treatment of performance-only SAD [<a href="#rid40">40</a>]. Beta-blockers are nonetheless used at times for the management of performance anxiety; clinical experience suggests that only half (or fewer) people find as-needed beta-blockers useful for performance anxiety.</p><p>Beta-adrenergic blockers may be most useful for patients who have prominent awareness of physiological symptoms such as tachycardia or tremor.</p><p><a class="drug drug_general" data-topicid="9829" href="/d/drug information/9829.html" rel="external">Propranolol</a> can be taken orally 30 to 60 minutes prior to the anxiety-inducing situation, at an initial dose of 10 or 20 mg. The patient should be encouraged to try out the medication in advance of a potentially precipitating event to determine how well it is tolerated and to see if it is efficacious. If tolerated but not sufficiently effective, increase the dose next time by 10 or 20 mg. Some patients may eventually require a dose of 60 mg. Contraindications to the prescription of beta-blockers include: a history of beta-blocker intolerance or allergy, diabetes, and certain cardiac conditions (eg, conduction problems). (See  <a class="medical medical_review" href="/d/html/967.html" rel="external">"Major side effects of beta blockers"</a>.)</p><p class="headingAnchor" id="H2567215378"><span class="h2">Cannabinoids</span><span class="headingEndMark"> — </span>A small, randomized, double-blind study of 600 mg cannabidiol (n = 12) versus placebo (n = 12) never-treated patients with SAD found that cannabidiol reduced anxiety during a public speaking task [<a href="#rid41">41</a>]. More recently, cannabidiol 300 mg oral (n = 39) versus placebo (n = 41) did not enhance the effects of exposure therapy on outcomes in a study that included patients with SAD and panic disorder with agoraphobia [<a href="#rid42">42</a>].</p><p class="headingAnchor" id="H951982565"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113096.html" rel="external">"Society guideline links: Anxiety and anxiety disorders in adults"</a>.)</p><p class="headingAnchor" id="H118961785"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/83069.html" rel="external">"Patient education: Social anxiety disorder (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H13590089"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monotherapy</strong> – Several classes of drugs are effective in the treatment of social anxiety disorder (SAD), including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), and benzodiazepines. (See <a class="local">'Monotherapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>SSRIs </strong>– Although some SSRIs have been more extensively studied than others in the treatment of SAD, there is no evidence of superiority of one SSRI over another. (See <a class="local">'Selective serotonin reuptake inhibitors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>SNRIs </strong>– Although less well studied than the SSRIs, the SNRI <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a> extended release appears to be equally effective for SAD on the basis of a comparable effect size compared with various SSRIs. (See <a class="local">'Serotonin-norepinephrine reuptake inhibitors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MAOIs</strong> – The MAOIs have the longest track record of use for SAD; however, side effects and dietary restrictions limit their use. MAOIs are generally reserved for SAD refractory to other treatments. (See <a class="local">'Monoamine oxidase inhibitors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Benzodiazepines</strong> – The high-potency benzodiazepines, <a class="drug drug_general" data-topicid="8453" href="/d/drug information/8453.html" rel="external">alprazolam</a> and <a class="drug drug_general" data-topicid="9284" href="/d/drug information/9284.html" rel="external">clonazepam</a>, have been found to be efficacious as monotherapy in the treatment of symptoms of SAD. For individuals with a history of benzodiazepine use or substance use disorder (SUD) we avoid treatment with benzodiazepines and use <a class="drug drug_general" data-topicid="8483" href="/d/drug information/8483.html" rel="external">gabapentin</a> or <a class="drug drug_general" data-topicid="9473" href="/d/drug information/9473.html" rel="external">pregabalin</a> as alternative treatment. (See <a class="local">'Benzodiazepines'</a> above and <a class="local">'Benzodiazepines and SUD history'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other agents with limited or mixed supporting data </strong>– <a class="drug drug_general" data-topicid="10059" href="/d/drug information/10059.html" rel="external">Moclobemide</a>, <a class="drug drug_general" data-topicid="9656" href="/d/drug information/9656.html" rel="external">mirtazapine</a>, beta blockers, tricyclic antidepressants, <a class="drug drug_general" data-topicid="9172" href="/d/drug information/9172.html" rel="external">buspirone</a>, second-generation antipsychotics, <a class="drug drug_general" data-topicid="8787" href="/d/drug information/8787.html" rel="external">atomoxetine</a>, and oxytocin have mixed or limited data supporting their use in the treatment of SAD. (See <a class="local">'Other agents'</a> above.)</p><p></p><p class="bulletIndent1">SSRIs, SNRIs, and MAOIs may take four to six weeks for an initial response and 12 to 16 weeks to achieve their full effect. We typically continue these and other medications for SAD for at least 6 to 12 months to decrease the likelihood of relapse. Some patients may need continuing treatment to maintain the gains achieved. (See <a class="local">'Monotherapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Augmentation </strong>– A substantial number of patients with SAD respond only partially to monotherapy. Clinical trials have found limited evidence supporting <a class="drug drug_general" data-topicid="9284" href="/d/drug information/9284.html" rel="external">clonazepam</a>, <a class="drug drug_general" data-topicid="9172" href="/d/drug information/9172.html" rel="external">buspirone</a>, and <a class="drug drug_general" data-topicid="8588" href="/d/drug information/8588.html" rel="external">ketamine</a> as augmenting agents. (See <a class="local">'Augmentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SAD, performance only </strong>– In the transition from American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) to DSM-5, the subtypes of generalized and nongeneralized SAD were replaced by SAD and SAD, performance only (specifier). (See <a class="local">'Social anxiety disorder, performance only'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest<strong> not treating </strong>performance-only SAD with medication. However, medication is a reasonable alternative if preferred by the patient or if a therapist trained to provide cognitive-behavioral therapy were not available.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>When medication is used to treat SAD, performance-only specifier, we suggest treatment with a benzodiazepine in patients who lack a history of an SUD (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with an SUD history or who experience sedation with a benzodiazepine, a beta-blocker is a reasonable alternative unless the patient has a contraindication to their use.</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ruscio AM, Brown TA, Chiu WT, et al. Social fears and social phobia in the USA: results from the National Comorbidity Survey Replication. Psychol Med 2008; 38:15.</a></li><li class="breakAll">American Psychiatric Association. DSM-5 Task Force. In: Diagnostic and Statistical Manual of Mental Disorders: DSM-5, 5th ed, American Psychiatric Association, Arlington 2013.</li><li><a class="nounderline abstract_t">Stein DJ, Ipser JC, Balkom AJ. Pharmacotherapy for social phobia. Cochrane Database Syst Rev 2004; :CD001206.</a></li><li><a class="nounderline abstract_t">Ravindran LN, Stein MB. The pharmacologic treatment of anxiety disorders: a review of progress. J Clin Psychiatry 2010; 71:839.</a></li><li><a class="nounderline abstract_t">Stein MB, Liebowitz MR, Lydiard RB, et al. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 1998; 280:708.</a></li><li><a class="nounderline abstract_t">Stein MB, Stein DJ. Social anxiety disorder. Lancet 2008; 371:1115.</a></li><li><a class="nounderline abstract_t">Mayo-Wilson E, Dias S, Mavranezouli I, et al. Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis. Lancet Psychiatry 2014; 1:368.</a></li><li><a class="nounderline abstract_t">Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 2005; 62:190.</a></li><li><a class="nounderline abstract_t">Liebowitz MR, Mangano RM, Bradwejn J, et al. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry 2005; 66:238.</a></li><li><a class="nounderline abstract_t">Stein MB, Pollack MH, Bystritsky A, et al. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl) 2005; 177:280.</a></li><li><a class="nounderline abstract_t">Blanco C, Heimberg RG, Schneier FR, et al. A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch Gen Psychiatry 2010; 67:286.</a></li><li><a class="nounderline abstract_t">Gelernter CS, Uhde TW, Cimbolic P, et al. Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study. Arch Gen Psychiatry 1991; 48:938.</a></li><li><a class="nounderline abstract_t">Davidson JR, Potts N, Richichi E, et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993; 13:423.</a></li><li><a class="nounderline abstract_t">Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999; 19:341.</a></li><li class="breakAll">United States Food and Drug Administration. FDA warns about serious breathing problems with seizure and nerve pain medicines gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR): When used with CNS depressants or in patients with lung problems. December 19, 2019. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin (Accessed on April 11, 2020).</li><li><a class="nounderline abstract_t">Pande AC, Feltner DE, Jefferson JW, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 2004; 24:141.</a></li><li><a class="nounderline abstract_t">Lydiard RB, Rickels K, Herman B, Feltner DE. Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int J Neuropsychopharmacol 2010; 13:229.</a></li><li><a class="nounderline abstract_t">Mula M, Pini S, Cassano GB. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J Clin Psychopharmacol 2007; 27:263.</a></li><li><a class="nounderline abstract_t">The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study. Eur Arch Psychiatry Clin Neurosci 1997; 247:71.</a></li><li><a class="nounderline abstract_t">Schneier FR, Goetz D, Campeas R, et al. Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry 1998; 172:70.</a></li><li><a class="nounderline abstract_t">Noyes R Jr, Moroz G, Davidson JR, et al. Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol 1997; 17:247.</a></li><li><a class="nounderline abstract_t">Muehlbacher M, Nickel MK, Nickel C, et al. Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2005; 25:580.</a></li><li><a class="nounderline abstract_t">Liebowitz MR, Schneier F, Campeas R, et al. Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry 1992; 49:290.</a></li><li><a class="nounderline abstract_t">Turner SM, Beidel DC, Jacob RG. Social phobia: a comparison of behavior therapy and atenolol. J Consult Clin Psychol 1994; 62:350.</a></li><li><a class="nounderline abstract_t">Vaishnavi S, Alamy S, Zhang W, et al. Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:1464.</a></li><li><a class="nounderline abstract_t">Barnett SD, Kramer ML, Casat CD, et al. Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol 2002; 16:365.</a></li><li><a class="nounderline abstract_t">Depping AM, Komossa K, Kissling W, Leucht S. Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst Rev 2010; :CD008120.</a></li><li><a class="nounderline abstract_t">van Vliet IM, den Boer JA, Westenberg HG, Pian KL. Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. J Clin Psychiatry 1997; 58:164.</a></li><li><a class="nounderline abstract_t">Ravindran LN, Kim DS, Letamendi AM, Stein MB. A randomized controlled trial of atomoxetine in generalized social anxiety disorder. J Clin Psychopharmacol 2009; 29:561.</a></li><li><a class="nounderline abstract_t">Adler LA, Liebowitz M, Kronenberger W, et al. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder. Depress Anxiety 2009; 26:212.</a></li><li><a class="nounderline abstract_t">Voncken MJ, Dijk C, Stöhr F, et al. The effect of intranasally administered oxytocin on observed social behavior in social anxiety disorder. Eur Neuropsychopharmacol 2021; 53:25.</a></li><li><a class="nounderline abstract_t">Guastella AJ, Howard AL, Dadds MR, et al. A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. Psychoneuroendocrinology 2009; 34:917.</a></li><li><a class="nounderline abstract_t">Van Ameringen M, Mancini C, Wilson C. Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord 1996; 39:115.</a></li><li><a class="nounderline abstract_t">Seedat S, Stein MB. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry 2004; 65:244.</a></li><li><a class="nounderline abstract_t">Pollack MH, Van Ameringen M, Simon NM, et al. A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. Am J Psychiatry 2014; 171:44.</a></li><li><a class="nounderline abstract_t">Stein MB, Sareen J, Hami S, Chao J. Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 2001; 158:1725.</a></li><li><a class="nounderline abstract_t">Taylor JH, Landeros-Weisenberger A, Coughlin C, et al. Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial. Neuropsychopharmacology 2018; 43:325.</a></li><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, 2013.</li><li class="breakAll">Ravindran LN, Stein MB. Anxiety Disorders: Somatic Treatment. In: Kaplan and Sadock Comprehensive Textbook of Psychiatry, 9th ed, Sadock BJ, Sadock VA, Ruiz P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, PA 2009. p.1906.</li><li><a class="nounderline abstract_t">Steenen SA, van Wijk AJ, van der Heijden GJ, et al. Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis. J Psychopharmacol 2016; 30:128.</a></li><li><a class="nounderline abstract_t">Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology 2011; 36:1219.</a></li><li><a class="nounderline abstract_t">Kwee CM, Baas JM, van der Flier FE, et al. Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: A randomised controlled trial. Eur Neuropsychopharmacol 2022; 59:58.</a></li></ol></div><div id="topicVersionRevision">Topic 505 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17976249" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Social fears and social phobia in the USA: results from the National Comorbidity Survey Replication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17976249" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Social fears and social phobia in the USA: results from the National Comorbidity Survey Replication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15495010" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pharmacotherapy for social phobia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20667290" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The pharmacologic treatment of anxiety disorders: a review of progress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9728642" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18374843" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Social anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26361000" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15699296" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15705011" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15258718" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20194829" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1929764" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8120156" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Treatment of social phobia with clonazepam and placebo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10440462" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Treatment of social phobia with gabapentin: a placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10440462" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Treatment of social phobia with gabapentin: a placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15206660" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19737439" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17502773" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9177952" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9534836" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Placebo-controlled trial of moclobemide in social phobia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9241002" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Moclobemide in social phobia: a controlled dose-response trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16282842" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1558463" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Phenelzine vs atenolol in social phobia. A placebo-controlled comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8201073" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Social phobia: a comparison of behavior therapy and atenolol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17698275" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12503837" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Efficacy of olanzapine in social anxiety disorder: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21154392" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Second-generation antipsychotics for anxiety disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9164427" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19910721" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A randomized controlled trial of atomoxetine in generalized social anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19194995" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34358819" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The effect of intranasally administered oxytocin on observed social behavior in social anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19246160" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8827420" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15003080" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24399428" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11579011" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28849779" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28849779" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28849779" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26487439" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21307846" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35561538" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cannabidiol enhancement of exposure therapy in treatment refractory patients with social anxiety disorder and panic disorder with agoraphobia: A randomised controlled trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
